Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug
By Katherine Hamilton
Outlook Therapeutics shares slid after the company's macular degeneration drug was once again rejected by the Food and Drug Administration.
The stock dropped 71% to 45 cents a share in after-hours trading. Through the close, shares had lost 16% this year.
The Iselin, N.J., biopharmaceutical company said Wednesday it received notice that the FDA wouldn't approve its biologics license application for ONS-5010/Lytenava, which is designed to treat wet age-related macular degeneration.
Outlook said the FDA was requesting more confirmatory evidence of the drug's efficacy, though it didn't provide details on what kind of evidence it was looking for.
In August, the FDA said it wouldn't approve the drug for similar reasons. Also, in 2023, the FDA turned away Outlook's initial application for ONS-5010, saying it had issues with chemistry, manufacturing and controls.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
December 31, 2025 17:20 ET (22:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
6 ETFs To Diversify Away From AI
Why This Vanguard ETF Is One of the Best
The Best AI Stocks to Buy Now
United States